DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy.

ABSTRACT:

Background

Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1 has recently become the new first-line standard of care therapy of pleural mesothelioma (PM) patients, with a significant improvement of overall survival (OS) over conventional chemotherapy. The analysis by tumor histotype demonstrated greater efficacy of ICI therapy compared to standard chemotherapy in non-epithelioid (non-E) vs. epithelioid (E) PM, although some E PM patients also benefit from ICI treatment. This evidence suggests that molecular tumor features, beyond histotype, could be relevant to improve the efficacy of ICI therapy in PM. Among these, tumor DNA methylation emerges as a promising factor to explore, due to its potential role in driving the immune phenotype of cancer cells. Therefore, w

SUBMITTER: Lofiego MF 

PROVIDER: S-EPMC11834541 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature